Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Gains from Sales and Divestitures (2022 - 2025)

Atara Biotherapeutics (ATRA) has disclosed Gains from Sales and Divestitures for 4 consecutive years, with $387204.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Gains from Sales and Divestitures rose 74.81% year-over-year to $387204.0, compared with a TTM value of $387204.0 through Sep 2025, up 74.81%, and an annual FY2024 reading of $315109.0, down 91.46% over the prior year.
  • Gains from Sales and Divestitures was $387204.0 for Q3 2025 at Atara Biotherapeutics, up from $282988.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $3.7 million in Q4 2023 and bottomed at $65580.0 in Q1 2025.
  • Average Gains from Sales and Divestitures over 4 years is $1.1 million, with a median of $480264.0 recorded in 2023.
  • The sharpest move saw Gains from Sales and Divestitures surged 225.97% in 2024, then tumbled 95.81% in 2025.
  • Year by year, Gains from Sales and Divestitures stood at $2.2 million in 2022, then skyrocketed by 64.11% to $3.7 million in 2023, then plummeted by 91.46% to $315109.0 in 2024, then rose by 22.88% to $387204.0 in 2025.
  • Business Quant data shows Gains from Sales and Divestitures for ATRA at $387204.0 in Q3 2025, $282988.0 in Q2 2025, and $65580.0 in Q1 2025.